This is unpublished

Creighton W.
Don
MD
PhD

Creighton Don portrait
Faculty
Pinned
Academic
Professor, Medicine
Professional
Section Chief of Cardiology, Puget Sound Veterans Administration Hospital
Attending Physician
Sites of Practice
VA Puget Sound Health Care System

CONTACTS

Mailing Address:

VA Puget Sound Health Care System
1660 S Columbian Way
Box 358280
Seattle, WA 98108-8280

Non-Clinical Administrative Support:
Rachel MacDonald

Clinical Contacts:
For appointments or other clinical matters, please contact the Heart Institute.

About

Creighton W. Don, M.D, PhD is an interventional cardiologist and Associate Professor of Medicine, Section Chief of Cardiology at the Puget Sound Veteran’s Administration Hospital in Seattle. and Director of the Interventional Cardiology and Structural Heart Fellowships at the University of Washington Medical Center in Seattle, WA. He completed his cardiology fellowship at the University of Washington and an interventional fellowship at Massachusetts General Hospital before joining UW Medicine in 2009. Dr. Don is an expert in complex coronary interventions including advanced therapies for instent restenosis and brachytherapy, percutaneous treatment for valvular heart disease (including TAVR, TMVR, TTVR, MitraClip, mitral annular devices), and other structural interventions such as left atrial appendage closure, PFO closure, and paravalvular leak closure. He earned an MPH at UW and his research focuses on evaluating outcomes in real world practice of patients undergoing complex coronary and structural heart procedures. He has been recognized in the Seattle Magazine as a Top Doctor in Seattle for interventional cardiology for several years.

Research Interests

  • PARTNER II study of the Edwards Sapien percutaneous aortic valve (minimally invasive treatment for patients with aortic valve stenosis at intermediate risk for traditional valve surgery)
  • RENEW study (using autologous CD34+ cells to treat chronic refractory angina in patients without revascularization options)
  • AIM-HIGH study (cardioprotective effects of the HDL raising drug, niacin)
  • Use of cell and biologic therapies for the treatment of severe atherosclerotic coronary artery disease not amenable to traditional revascularization
  • OASIS-7 CURRENT study of copidogrel dosing in patients with non-ST-elevation myocardial infarction, and is involved in evaluating hospital registries designed to improve quality of care for patients undergoing percutaneous coronary interventions

Publications

PubMed